SEARCH

SEARCH BY CITATION

References

  • 1
    Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Health 2001;4:22550.
  • 2
    Claxton K, Neuman PJ, Araki SS, Weinstein MC. The value of information: an application to a policy model of Alzheimer’s disease. Int J Technol Assess Health Care 2001;17:3855.
  • 3
    Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996;5:51324.
  • 4
    Claxton K, Eggington S, Ginnelly L, et al. A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Clinical Excellence. 2004. Available from: http://www.nice.org.uk[Accessed September 1, 2005].
  • 5
    NICE. Guide to the Technology Appraisal Process. London: National Institute for Clinical Excellence, 2004.
  • 6
    NICE. Guide to the Methods of Technology Appraisal. London: National Institute for Clinical Excellence, 2004.
  • 7
    Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14:33947.
  • 8
    Bedford T, Cooke R. Probabilistic Risk Analysis: Foundations and Methods. Cambridge: Cambridge University Press, 2001.
  • 9
    Ginnelly L. Characterising Structural Uncertainty in Decision Analytic Models: Review and Application of Currently Available Methods. Oxford: Health Economists’ Study Group, January 2005.
  • 10
    Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:34264.
  • 11
    Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty—when is there sufficient evidence? Value Health 2005;8:43346.
  • 12
    Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004;82:66187.
  • 13
    Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290308.
  • 14
    Stevenson M, Oakley J, Chilcott J. Gaussian process modeling in conjunction with individual patient simulation modeling. a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 2004; 24:89100.
  • 15
    Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making 2004;24:20727.
  • 16
    Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastro-intestinal stromal tumours—a systematic review and economic evaluation. 2003. Available from: http://www.nice.org.uk[Accessed September 1, 2005].
  • 17
    Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:47280.
  • 18
    Stevenson M, Jones M, De Nigris E, et al. The clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis. 2004. Available from: http://www.nice.org.uk[Accessed September 1, 2005].
  • 19
    Kanis J, Brazier J, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002; 6(29):1146.
  • 20
    Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6(21):1110.
  • 21
    Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults. 2004. Available from: http://www.nice.org.uk[Accessed September 1, 2005].
  • 22
    Bryan S, Connock M, Cummins C, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. 2004. Available from: http://www.nice.org.uk[Accessed September 1, 2005].
  • 23
    Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9.
  • 24
    Development Core Team. A Language and Environment for Statistical Computing. Vienna: R Development Core Team, 2004.
  • 25
    Hawkins N, Sculpher M, Epstein D. Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response. Med Decis Making 2005;25:51120.
  • 26
    Hawkins N, Epstein D, Drummond M, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results a probabilistic decision model. Med Decis Making 2005;25:493511.
  • 27
    Borland Software Corporation. Borland Delphi. Scotts Valley, CA: Borland Software Corporation, 2004.
  • 28
    Treeage Software, Inc. TreeAge DATA 3.5. Williamstown, MN: Treeage Software, Inc., 2004.
  • 29
    Hill R, Bagust A, Bakhai A et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004;8:iiiiv; 1–242.